1. (currently amended) A compound of the formula I,



I

in which

W, X, Y are, independently of one another, O or S;

R9, R10, R11, R12 are, independently of one another, H, F, Cl, Br, OH, CF_3, NO_2, CN, OCF_3, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, O-(C_2-C_6)-alkynyl, O-SO_2-(C_1-C_4)-alkyl, O-SO_2-phenyl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF_3, OCF_3, COOR13 or CON(R14)(R15), or S-(C_1-C_6)-alkyl, S-(C_2-C_6)-alkenyl, S-(C_2-C_6)-alkynyl, SO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, SO_2-NH_2, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl, (C_0-C_6)-alkylene-COOR13, CON(R14)(R15), (C_0-C_6)-alkylene-N(R14)(R15), NH-COR13, NH-CO-phenyl, NH-SO_2-phenyl or phenyl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF_3, OCF_3, COOR13 or CON(R14)(R15);

R13 is H, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl or (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl;

R1, R2 are, independently of one another, H, (C_1-C_6)-alkyl, where alkyl may be substituted by OH, O-(C_1-C_4)-alkyl or N(R14)(R15), or O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, O-(C_2-C_6)-alkynyl, CO-(C_1-C_6)-alkyl, CO-(C_2-C_6)-alkenyl, CO-(C_2-C_6)-alkynyl, COOR13 or (C_0-C_6)-alkylene-COOR13;

R3, R4, R5, R6 are, independently of one another, H, OH, CF_3, NO_2, CN, OCF_3, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_{10})-alkyl, O-(C_2-C_{10})-alkenyl, O-(C_2-C_{10})-alkynyl, S-(C_1-C_6)-alkyl, S-(C_2-C_6)-alkenyl, S-(C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-

cycloalkyl-(C_1-C_4)-alkyl, where alkyl, alkenyl, alkynyl and cycloalkyl may be substituted more than once by F, Cl, Br, SO-phenyl, SO_2-phenyl, where the phenyl ring may be substituted by F, Cl, Br or R13, or OR13, COOR13, CON(R14)(R15), N(R14)(R15) or CO-heteroalkyl, or are O-SO-(C_1-C_6)-alkyl, O-SO_2-(C_1-C_6)-alkyl, O-SO_2-(C_6-C_{10})-aryl, O-(C_6-C_{10})-aryl, where aryl may be substituted up to twice by F, Cl, CN, OR13, R13, CF_3 or OCF_3, or are SO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, SO_2-(C_6-C_{10})-aryl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF_3, OCF_3, COOR13 or CON(R14)(R15), or are SO_2-N(R14)(R15), COOR13, CO-heteroalkyl, N(R14)(R15) or heteroalkyl;

R14, R15 are, independently of one another, H, (C_1-C_6)-alkyl, where alkyl may be substituted by $N(R13)_2$, or are (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkylene-OCO-(C_1-C_6)-alkyl, CO-phenyl, COO-phenyl, COO-(C_1-C_6)-alkenyl-phenyl, OH, O-(C_1-C_6)-alkyl, O-(C_1-C_6)-alkenyl-phenyl or NH_2;

or the radicals R14 and R15 form with the nitrogen atom to which they are bonded a 3-7-membered, saturated heterocyclic ring which may comprise up to 2 further heteroatoms from the group of N, O or S, where the heterocyclic ring may be substituted up to three times by F, Cl, Br, OH, oxo, N(R16)(R17) or (C_1-C_4)-alkyl;

R16, R17 are, independently of one another, H, (C_1-C_6)-alkyl, where alkyl may be substituted by $N(R13)_2$, or are (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkylene-OCO-(C_1-C_6)-alkyl, CO-phenyl, COO-phenyl, COO-(C_1-C_6)-alkenyl-phenyl, OH, O-(C_1-C_6)-alkyl, O-(C_1-C_6)-alkenyl-phenyl or NH_2;

heteroalkyl is a 3-7-membered, saturated or up to triunsaturated heterocyclic ring which may comprise up to 4 heteroatoms which correspond to N, O or S, where the heterocyclic ring may be substituted at all sensible positions up to three times by F, Cl, Br, CN, oxo, (C_1-C_4)-alkyl, (C_0-C_4)-alkylene-COOR13, CON(R14)(R15), OR13, N(R14)(R15) or phenyl, where phenyl may be substituted by COOR13;

R7 is H, (C_1-C_6)-alkyl, where alkyl may be substituted by OR13 or N(R14)(R15), or is O-(C_1-C_6)-alkyl, CO-(C_1-C_6)-alkyl or (C_0-C_6)-alkylene-COOR13;

R8 is N(R18)(R19);

R18, R19 are, independently of one another, H, $(C_1$-$C_{10})$-alkyl, $(C_2$-$C_{10})$-alkenyl, $(C_2$-$C_{10})$-alkynyl, $(C_3$-$C_7)$-cycloalkyl, $(C_3$-$C_7)$-cycloalkyl-$(C_1$-$C_6)$-alkyl, $(C_6$-$C_{10})$-aryl, $(C_6$-$C_{10})$-aryl-$(C_1$-$C_4)$-alkyl, $(C_6$-$C_{10})$-aryl-$(C_2$-$C_4)$-alkenyl, $(C_6$-$C_{10})$-aryl-$(C_2$-$C_4)$-alkynyl, heteroaryl, heteroaryl-$(C_1$-$C_4)$-alkyl, heteroaryl-$(C_2$-$C_4)$-alkenyl, heteroaryl-$(C_2$-$C_4)$-alkynyl, where alkyl, alkenyl, alkynyl and cycloalkyl may be substituted more than once by F, Cl, CN, OR13, R13, CF_3, OCF_3, $(C_6$-$C_{10})$-aryl, NH-C(=NR14)-N(R14)(R15), N(R14)(R15), C(=NR14)-N(R14)(R15), COOR13 or CON(R14)(R15), and where aryl may be substituted more than once by F, Cl, CN, O-$(C_1$-$C_6)$-alkyl, O-$(C_2$-$C_6)$-alkenyl, $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, CO-$(C_1$-$C_6)$-alkyl, CO-$(C_2$-$C_6)$-alkenyl, where alkyl and alkenyl may be substituted more than once by F, Cl, CH_3, OCH_3 or CN, or NH-C(=NR14)-N(R14)(R15), N(R14)(R15), C(=NR14)-N(R14)(R15), COOR13, CON(R14)(R15), O-phenyl, phenyl or pyridyl; COOR13, CON-(R14)(R15), CO-heteroalkyl, CO-$(C_6$-$C_{10})$-aryl or SO_2-$(C_6$-$C_{10})$-aryl, where aryl may be substituted up to twice by F, Cl, CN, OH, $(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_6)$-alkyl, CF_3, OCF_3, COOR13 or CON(R14)(R15);

or the radicals R18 and R19 form with the nitrogen atom to which they are bonded a 3-7-membered, saturated heterocyclic ring which may comprise up to 2 further heteroatoms from the group of N, O or S, where the heterocyclic ring may be substituted up to three times by F, Cl, Br, OH, oxo, N(R16)(R17) or $(C_1$-$C_4)$-alkyl;

or a pharmaceutically acceptable salt thereof,

provided the radicals R3, R4, R5, R6, R7, X, Y and R8 do not have the following meanings at the same time:

R3, R4 or R5 is CF_3;

R6 is H or CF_3;

R7 is H;

X is O; and

Y is O, S;

R8 is substituted or unsubstituted NH-phenyl wherein either the nitrogen atom or the phenyl ring is substituted or unsubstituted.

2. (previously presented) A compound of the formula I as claimed in claim 1, wherein said compound has the structure of compound Ia:



Ia

wherein

R9 is F, Cl, Br, OH, CF_3, NO_2, CN, OCF_3, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, O-(C_2-C_6)-alkynyl, O-SO_2-(C_1-C_4)-alkyl, O-SO_2-phenyl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF_3, OCF_3, COOR13 or CON(R14)(R15), or S-(C_1-C_6)-alkyl, S-(C_2-C_6)-alkenyl, S-(C_2-C_6)-alkynyl, SO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, SO_2-NH_2, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl, -COOR13, (C_1-C_6)-alkylene-COOR13, CON(R14)(R15), -N(R14)(R15), (C_1-C_6)-alkylene-N(R14)(R15), NH-COR13, NH-CO-phenyl, NH-SO_2-phenyl or phenyl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF_3, OCF_3, COOR13 or CON(R14)(R15);

R10, R11, R12 independently of one another are H, F, Cl, Br, OH, CF_3, NO_2, CN, OCF_3, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, O-(C_2-C_6)-alkynyl, O-SO_2-(C_1-C_4)-alkyl, O-SO_2-phenyl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF_3, OCF_3, COOR13 or CON(R14)(R15), or S-(C_1-C_6)-alkyl, S-(C_2-C_6)-alkenyl, S-(C_2-C_6)-alkynyl, SO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, SO_2-NH_2, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl, COOR13, (C_1-C_6)-alkylene-COOR13, CON(R14)(R15), N(R14)(R15), (C_1-C_6)-alkylene-N(R14)(R15), NH-COR13, NH-CO-phenyl, NH-SO_2-phenyl or phenyl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF_3, OCF_3, COOR13 or CON(R14)(R15);

R13 is H, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl or (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl;

R3, R4, R5, are independently of one another H, OH, CF_3, NO_2, CN, OCF_3, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_{10})-alkyl, O-(C_2-C_{10})-alkenyl, O-(C_2-C_{10})-alkynyl, S-(C_1-C_6)-alkyl, S-(C_2-C_6)-alkenyl, S-(C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl, where alkyl, alkenyl, alkynyl and cycloalkyl may be substituted more than once by F, Cl, Br, SO-phenyl, SO_2-phenyl, where the phenyl ring may be substituted by F, Cl, Br or R13, or OR13, COOR13, CON(R14)(R15), N(R14)(R15) or CO-heteroalkyl, or O-SO-(C_1-C_6)-alkyl, O-SO_2-(C_1-C_6)-alkyl, O-SO_2-(C_6-C_{10})-aryl, O-(C_6-C_{10})-aryl, where aryl may be substituted up to twice by F, Cl, CN, OR13, R13, CF_3 or OCF_3, or SO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, SO_2-(C_6-C_{10})-aryl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF_3, OCF_3, COOR13 or CON(R14)(R15), or SO_2-N(R14)(R15), COOR13, CO-heteroalkyl, N(R14)(R15) or heteroalkyl;

R6 is OH, CF_3, NO_2, CN, OCF_3, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, O-(C_1-C_{10})-alkyl, O-(C_2-C_{10})-alkenyl, O-(C_2-C_{10})-alkynyl, S-(C_1-C_6)-alkyl, S-(C_2-C_6)-alkenyl, S-(C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl, where alkyl, alkenyl, alkynyl and cycloalkyl may be substituted more than once by F, Cl, Br, SO-phenyl, SO_2-phenyl, where the phenyl ring may be substituted by F, Cl, Br or R13, or OR13, COOR13, CON(R14)(R15), N(R14)(R15) or CO-heteroalkyl, or O-SO-(C_1-C_6)-alkyl, O-SO_2-(C_1-C_6)-alkyl, O-SO_2-(C_6-C_{10})-aryl, O-(C_6-C_{10})-aryl, where aryl may be substituted up to twice by F, Cl, CN, OR13, R13, CF_3 or OCF_3, or SO-(C_1-C_6)-alkyl, SO_2-(C_1-C_6)-alkyl, SO_2-(C_6-C_{10})-aryl, where the phenyl ring may be substituted up to twice by F, Cl, Br, CN, OR13, R13, CF_3, OCF_3, COOR13 or CON(R14)(R15), or SO_2-N(R14)(R15), COOR13, CO-heteroalkyl, N(R14)(R15) or heteroalkyl;

R14, R15 independently of one another are H, (C_1-C_6)-alkyl, where alkyl may be substituted by $N(R13)_2$, or (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkylene-OCO-(C_1-C_6)-alkyl, CO-phenyl, COO-phenyl, COO-(C_1-C_6)-alkenyl-phenyl, OH, O-(C_1-C_6)-alkyl, O-(C_1-C_6)-alkenyl-phenyl or NH_2;

or the radicals R14 and R15 form with the nitrogen atom to which they are bonded a 3-7-membered, saturated heterocyclic ring which may comprise up to 2 further heteroatoms from the

group of N, O or S, where the heterocyclic ring may be substituted up to three times by F, Cl, Br, OH, oxo, N(R16)(R17) or (C_1-C_4)-alkyl;

R16, R17 independently of one another are H, (C_1-C_6)-alkyl, where alkyl may be substituted by $N(R13)_2$, or (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl, CO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkyl, COO-(C_1-C_6)-alkylene-OCO-(C_1-C_6)-alkyl, CO-phenyl, COO-phenyl, COO-(C_1-C_6)-alkenyl-phenyl, OH, O-(C_1-C_6)-alkyl, O-(C_1-C_6)-alkenyl-phenyl or NH_2;

heteroalkyl is a 3-7-membered, saturated or up to triunsaturated heterocyclic ring which may comprise up to 4 heteroatoms selected from N, O or S, where the heterocyclic ring may be substituted up to three times by F, Cl, Br, CN, oxo, (C_1-C_4)-alkyl, COOR13, (C_1-C_4)-alkylene-COOR13, CON(R14)(R15), OR13 or N(R14)(R15) or phenyl, where phenyl may be substituted by COOR13;

R8 is N(R18)(R19);

R18, R19 independently of one another are H, (C_1-C_{10})-alkyl, (C_2-C_{10})-alkenyl, (C_2-C_{10})-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_6)-alkyl, (C_6-C_{10})-aryl, (C_6-C_{10})-aryl-(C_1-C_4)-alkyl, (C_6-C_{10})-aryl-(C_2-C_4)-alkenyl, (C_6-C_{10})-aryl-(C_2-C_4)-alkynyl, heteroaryl, heteroaryl-(C_1-C_4)-alkyl, heteroaryl-(C_2-C_4)-alkenyl, heteroaryl-(C_2-C_4)-alkynyl, where alkyl, alkenyl, alkynyl and cycloalkyl may be substituted more than once by F, Cl, CN, OR13, R13, CF_3, OCF_3, (C_6-C_{10})-aryl, NH-C(=NR14)-N(R14)(R15), N(R14)(R15), C(=NR14)-N(R14)(R15), COOR13 or CON(R14)(R15), and where aryl may be substituted more than once by F, Cl, CN, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, CO-(C_1-C_6)-alkyl, CO-(C_2-C_6)-alkenyl, where alkyl and alkenyl may be substituted more than once by F, Cl, CH_3, OCH_3 or CN, or NH-C(=NR14)-N(R14)(R15), N(R14)(R15), C(=NR14)-N(R14)(R15), COOR13, CON(R14)(R15), O-phenyl, phenyl or pyridyl;
COOR13, CON-(R14)(R15), CO-heteroalkyl, CO-(C_6-C_{10})-aryl or SO_2-(C_6-C_{10})-aryl, where aryl may be substituted up to twice by F, Cl, CN, OH, (C_1-C_6)-alkyl, O-(C_1-C_6)-alkyl, CF_3, OCF_3, COOR13 or CON(R14)(R15);

or the radicals R18 and R19 form together with the nitrogen atom to which they are bonded a 3-7-membered, saturated heterocyclic ring which may comprise up to 3 heteroatoms

selected from the group of N, O or S, where the heterocyclic ring may be substituted up to three times by F, Cl, Br, OH, oxo, N(R16)(R17) or (C_1-C_4)-alkyl;

or a pharmaceutically acceptable salt thereof,

provided the radical R8 is not substituted or unsubstituted NH-phenyl wherein either the nitrogen atom or the phenyl ring is substituted or unsubstituted.

3. (previously presented) A compound of the formula Ia as claimed in claim 2, wherein

R9, R10, R11 independently of one another are F or Cl;

R12 is H;

R13 is H, (C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, (C_3-C_7)-cycloalkyl or (C_3-C_7)-cycloalkyl-(C_1-C_4)-alkyl;

R14, R15 independently of one another are H or (C_1-C_6)-alkyl, where alkyl may be substituted by $N(R13)_2$;

heteroalkyl is a 3-7-membered, saturated or up to triunsaturated heterocyclic ring which may comprise up to 4 heteroatoms selected from N, O or S, where the heterocyclic ring may be substituted up to three times by F, Cl, Br, CN, oxo, (C_1-C_4)-alkyl, COOR13, (C_1-C_4)-alkylene-COOR13, CON(R14)(R15), OR13 or N(R14)(R15) or phenyl, where phenyl may be substituted by COOR13;

R8 is N(R18)(R19;

R18, R19 independently of one another are H, (C_1-C_{10})-alkyl, (C_2-C_{10})-alkenyl, (C_2-C_{10})-alkynyl, (C_3-C_7)-cycloalkyl, (C_3-C_7)-cycloalkyl-(C_1-C_6)-alkyl, (C_6-C_{10})-aryl, (C_6-C_{10})-aryl-(C_1-C_4)-alkyl, (C_6-C_{10})-aryl-(C_2-C_4)-alkenyl, (C_6-C_{10})-aryl-(C_2-C_4)-alkynyl, heteroaryl, heteroaryl-(C_1-C_4)-alkyl, heteroaryl-(C_2-C_4)-alkenyl, heteroaryl-(C_2-C_4)-alkynyl, where alkyl, alkenyl, alkynyl and cycloalkyl may be substituted more than once by F, Cl, CN, OR13, R13, CF_3, OCF_3, (C_6-C_{10})-aryl, NH-C(=NR14)-N(R14)(R15), N(R14)(R15), C(=NR14)-N(R14)(R15), COOR13 or CON(R14)(R15), and where aryl may be substituted more than once by F, Cl, CN, O-(C_1-C_6)-alkyl, O-(C_2-C_6)-alkenyl,

$(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, CO-$(C_1$-$C_6)$-alkyl, CO-$(C_2$-$C_6)$-alkenyl, where alkyl and alkenyl may be substituted more than once by F, Cl, CH_3, OCH_3 or CN, or NH-C(=NR14)-N(R14)(R15), N(R14)(R15), C(=NR14)-N(R14)(R15), COOR13, CON(R14)(R15), O-phenyl, phenyl or pyridyl;

COOR13, CON-(R14)(R15), CO-heteroalkyl, CO-$(C_6$-$C_{10})$-aryl or SO_2-$(C_6$-$C_{10})$-aryl, where aryl may be substituted up to twice by F, Cl, CN, OH, $(C_1$-$C_6)$-alkyl, O-$(C_1$-$C_6)$-alkyl, CF_3, OCF_3, COOR13 or CON(R14)(R15);

or the radicals R18 and R19 form together with the nitrogen atom to which they are bonded a 3-7-membered, saturated heterocyclic ring which may comprise up to 3 heteroatoms selected from the group of N, O or S, where the heterocyclic ring may be substituted up to three times by F, Cl, Br, OH, oxo, N(R16)(R17) or $(C_1$-$C_4)$-alkyl.

4. (previously presented) A pharmaceutical composition comprising one or more of the compounds as claimed in claim 1 and an acceptable carrier.

5. (withdrawn) A pharmaceutical composition comprising one or more of the compounds as claimed in claim 1, an acceptable carrier, and at least one other active ingredient.

6. (withdrawn) A pharmaceutical composition as claimed in claim 5, wherein the other active ingredient comprises one or more antidiabetics, hypoglycemic active ingredients, HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP-citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones, α-glucosidase inhibitors, active ingredients which act on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotoninergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, decoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR-β agonists or amphetamines.

7. (original) A process for producing a pharmaceutical composition comprising mixing one or more of the compounds as claimed in claim 1 with an active ingredient and a pharmaceutically suitable carrier and converting this mixture into a suitable for administration.

8. (withdrawn) A method for reducing blood glucose, comprising administering to a subject in need thereof, one or more compounds claimed in claim 1.

9. (withdrawn) A method for treating type 2 diabetes, comprising administering to a subject in need thereof, one or more compounds claimed in claim 1.

10. (withdrawn) A method for treating disturbances of lipid and carbohydrate metabolism, comprising administering to a subject in need thereof, one or more compounds claimed in claim 1.

11. (withdrawn) A method for treatin arteriosclerotic manifestations, comprising administering to a subject in need thereof, one or more compounds claimed in claim 1.

12. (withdrawn) A method for treating insulin resistance, comprising administering to a subject in need thereof, one or more compounds claimed in claim 1.